Literature DB >> 26666822

Clinicopathological significance of p38β, p38γ, and p38δ and its biological roles in esophageal squamous cell carcinoma.

Shutao Zheng1,2, Chenchen Yang1,2, Tao Liu1,2, Qing Liu1,2, Fang Dai1,2, Ilyar Sheyhidin2, Xiaomei Lu3,4,5.   

Abstract

P38β, p38γ, and p38δ have been sporadically and scarcely reported to be involved in the carcinogenesis of cancers, compared with p38α isoform. However, little has been known regarding their clinicopathological significance and biological roles in esophageal squamous cell carcinoma (ESCC). Expression status of p38β, p38γ, and p38δ was assayed using immunohistochemistry with ESCC tissue microarray; ensuing clinicopathological significance was statistically analyzed. To define its biological roles on proliferation, migration and invasion of ESCC cell line Eca109 in vitro, MTT, wound healing, and Transwell assays were employed, respectively. As confirmation, athymic nude mice were taken to verify the effect over proliferation in vivo. It was found that both p38β and p38δ expression, other than p38γ, were significantly higher in ESCC tissues compared with paired normal controls. In terms of prognosis, only p38β expression was observed to be significantly associated with overall prognosis. Clinicopathologically, there was significant association between p38γ expression and clinical stage, lymph nodes metastases, and tumor volume. No significant association was found for p38β and p38δ between its expression and other clinicopathological parameters other than significant difference of expression between ESCC versus normal control. In Eca109, it was observed that p38β, p38γ, and p38δ can promote the cell growth and motility. As verification, over-expression of p38δ can promote, whereas knockdown of p38γ can prevent, the tumorigenesis in nude mice model xenografted with Eca109 cells whose basal level of p38δ was stably over-expressed and p38γ was stably knocked down. Together, our results demonstrate that p38β, p38γ, and p38δ played oncogenic roles in ESCC.

Entities:  

Keywords:  Esophageal squamous cell carcinoma; Metastasis; Prognosis; p38β; p38γ; p38δ

Mesh:

Substances:

Year:  2015        PMID: 26666822     DOI: 10.1007/s13277-015-4610-9

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  36 in total

1.  Tissue microarray is inappropriate for analysis of BCL6 expression in diffuse large B-cell lymphoma.

Authors:  Johan Linderoth; Mats Ehinger; Måns Akerman; Eva Cavallin-Ståhl; Gunilla Enblad; Martin Erlanson; Mats Jerkeman
Journal:  Eur J Haematol       Date:  2007-08       Impact factor: 2.997

2.  Tumor cell p38 MAPK: A trigger of cancer bone osteolysis.

Authors:  Huan Liu; Jin He; Jing Yang
Journal:  Cancer Cell Microenviron       Date:  2015-01-01

3.  p38γ mitogen-activated protein kinase contributes to oncogenic properties maintenance and resistance to poly (ADP-ribose)-polymerase-1 inhibition in breast cancer.

Authors:  Fanyan Meng; Haijun Zhang; Gang Liu; Bas Kreike; Wei Chen; Seema Sethi; Fred R Miller; Guojun Wu
Journal:  Neoplasia       Date:  2011-05       Impact factor: 5.715

4.  Inhibition of the p38 kinase suppresses the proliferation of human ER-negative breast cancer cells.

Authors:  Lu Chen; Julie Ann Mayer; Tibor I Krisko; Corey W Speers; Tao Wang; Susan G Hilsenbeck; Powel H Brown
Journal:  Cancer Res       Date:  2009-11-17       Impact factor: 12.701

Review 5.  The p38 MAPK stress pathway as a tumor suppressor or more?

Authors:  Mathew Loesch; Guan Chen
Journal:  Front Biosci       Date:  2008-05-01

6.  Mechanisms of platelet-stimulated colon cancer invasion: role of clusterin and thrombospondin 1 in regulation of the P38MAPK-MMP-9 pathway.

Authors:  Aneta Radziwon-Balicka; Maria J Santos-Martinez; J Jose Corbalan; Shane O'Sullivan; Achim Treumann; John F Gilmer; Marek W Radomski; Carlos Medina
Journal:  Carcinogenesis       Date:  2013-10-01       Impact factor: 4.944

7.  p38γ overexpression in gliomas and its role in proliferation and apoptosis.

Authors:  Kui Yang; Yunsheng Liu; Zhixiong Liu; Jinfang Liu; Xin Liu; Xin Chen; Chuntao Li; Yu Zeng
Journal:  Sci Rep       Date:  2013       Impact factor: 4.379

Review 8.  p38δ MAPK: Emerging Roles of a Neglected Isoform.

Authors:  Carol O'Callaghan; Liam J Fanning; Orla P Barry
Journal:  Int J Cell Biol       Date:  2014-09-17

9.  The F1000Research Antibody Validation Article Collection.

Authors:  Matthew A Helsby; Mei Yee Leung; Andrew D Chalmers
Journal:  F1000Res       Date:  2014-10-13

10.  p38δ MAPK phenotype: an indicator of chemotherapeutic response in oesophageal squamous cell carcinoma.

Authors:  Carol O'Callaghan; Liam J Fanning; Orla P Barry
Journal:  Anticancer Drugs       Date:  2015-01       Impact factor: 2.248

View more
  5 in total

1.  Targeting the non-ATP-binding pocket of the MAP kinase p38γ mediates a novel mechanism of cytotoxicity in cutaneous T-cell lymphoma (CTCL).

Authors:  Xu Hannah Zhang; Chih-Hong Chen; Hongzhi Li; Jack Hsiang; Xiwei Wu; Weidong Hu; David Horne; Sangkil Nam; Jack Shively; Steven T Rosen
Journal:  FEBS Lett       Date:  2021-09-15       Impact factor: 3.864

2.  DNMT1 and p38γ are inversely expressed in reactive non-metastatic lymph nodes burdened with colorectal adenocarcinoma.

Authors:  Xu Hannah Zhang; Zhirong Yin; Aimin Zhang; Raju Pillai; Brian Armstrong; Steven T Rosen
Journal:  EJHaem       Date:  2020-06-29

3.  Partition-Defective 3 (PARD3) Regulates Proliferation, Apoptosis, Migration, and Invasion in Esophageal Squamous Cell Carcinoma Cells.

Authors:  Lei Wang; Haiping Zhang; Ayshamgul Hasim; Abuduaini Tuerhong; Zhichao Hou; Ablajan Abdurahmam; Ilyar Sheyhidin
Journal:  Med Sci Monit       Date:  2017-05-20

Review 4.  The Role of p38γ in Cancer: From review to outlook.

Authors:  Wentao Xu; Rui Liu; Ying Dai; Shaocheng Hong; Huke Dong; Hua Wang
Journal:  Int J Biol Sci       Date:  2021-09-23       Impact factor: 6.580

5.  Multi-Kinase Inhibitor with Anti-p38γ Activity in Cutaneous T-Cell Lymphoma.

Authors:  Xu Hannah Zhang; Sangkil Nam; Jun Wu; Chih-Hong Chen; Xuxiang Liu; Hongzhi Li; Timothy McKeithan; Qiang Gong; Wing C Chan; Hongwei Holly Yin; Yate-Ching Yuan; Raju Pillai; Christiane Querfeld; David Horne; Yuan Chen; Steven T Rosen
Journal:  J Invest Dermatol       Date:  2018-07-14       Impact factor: 7.590

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.